Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroendocrine Tumors 4Carcinoid Tumor 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenoma, Islet Cell 1Adenocarcinoma 1Acromegaly 1

Interventions

Tamoxifen 2Specimen Handling 2Neoadjuvant Therapy 2poly ICLC 1pasireotide 1liposomal doxorubicin 1exemestane 1Vorinostat 1UAB 30 1Surgical Procedures, Operative 1Sulindac 1Selective Estrogen Receptor Modulators 1Ritonavir 1Petrolatum 1Letrozole 1Immunohistochemistry 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Biopsy 1Bexarotene 1Atorvastatin 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Intraductal, Noninfiltrating × pasireotide × Clear all
NCT01372644 2016-12-05

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NYU Langone Health

Phase 1 Completed
15 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡